Outcomes of allogenic hematopoietic cell transplantation for childhood chronic myeloid leukemia: Single-center experience.

Hanafy A Hafez Amr AbdallaMahmoud HammadNayera HamdyDina YassinSherine SalemOmayma HassanainLama ElhalabyAlaa Elhaddad

Published in: Pediatric transplantation (2020)

Considering the excellent survival rates and very low TRM, HSCT is still a valid option for pediatric patients with newly diagnosed CML with best using marrow stem cell source to avoid a significant risk of cGVHD and its related complications.

Keyphrases

chronic myeloid leukemia
newly diagnosed
stem cells
childhood cancer
risk factors
early life
free survival
hematopoietic stem cell
adipose tissue
glycemic control
drug induced